Article
PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis.
Critical reviews in oncology/hematology - 1 Feb 2022
Deng Hongsheng, Zhao Yi, Cai Xiuyu, Chen Hualin, Cheng Bo, Zhong Ran, Li Feng, Xiong Shan, Li Jianfu, Liu Jun, He Jianxing, Liang Wenhua
Abstract excerpt
To date, there is no approved biomarker for predicting pathological response in neoadjuvant programmed cell death (ligand) 1 (PD-(L)1) blockades treated early-stage non-small cell lung cancer (NSCLC). Databases including PubMed, Embase, ClinicalTrials.gov, and Conference abstracts were searched for clinical trials of neoadjuvant PD-1/PD-L1 blockades for resectable NSCLC. Data regarding major pathological response...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.